OPK back at the .236 fib line, which has been a clear area of support/resistance. The question is, will the speculation on its testing company end up giving the boost needed to push back above the $5 mark or is this truly a "fib" and OPK falls back down heading into the rest of March?"Ongoing pressure from an activist investor to offload its BioReference unit has also become a source of speculation. This stemmed from recent M&A action within the diagnostics space earlier this month. Needless to say, the recent action in the stock has continued supporting some analysts’ bullish stances on the company. Most recently, Barrington Research boosted its price target to $8 from $7 and maintained its Outperform rating."
Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。